AstraZeneca PLC (AZN) operating KPIs

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30

$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca lokelma (sodium zirconium cyclosilicate) — Worldwide product sales ($M) ($M)

Form 6-K Quarterly & Form 20-F Product Sales by Medicine & Region Tables

Quarterly Annual

Latest, Q2 2026

221

Period ended Jun 30, 2026

Change on a year earlier

+26.3%

175 in Q2 2025

History

29 quarters

Since Q2 2019

Sources

Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

Period	Ended	Lokelma (sodium zirconium cyclosilicate) — Worldwide product sales ($M) ($M)	Year on year	Source
Q2 2026	Jun 30, 2026	221	+26.3%	Form 6-K FY2026Q2 Earnings Release ↗
Q1 2026	Mar 31, 2026	199	+30.1%	Form 6-K FY2026Q1 Earnings Release ↗
Q4 2025	Dec 31, 2025	181	+20.7%	Form 6-K FY2025Q4 Earnings Release ↗
Q3 2025	Sep 30, 2025	189	+32.2%	Form 6-K FY2025Q3 Earnings Release ↗
Q2 2025	Jun 30, 2025	175	+28.7%	Form 6-K FY2025Q2 Earnings Release ↗
Q1 2025	Mar 31, 2025	153	+34.2%	Form 6-K FY2025Q1 Earnings Release ↗
Q4 2024	Dec 31, 2024	150	+33.9%	Form 6-K FY2024Q4 Earnings Release ↗
Q3 2024	Sep 30, 2024	143	+40.2%	Form 6-K FY2024Q3 Earnings Release ↗
Q2 2024	Jun 30, 2024	136	+36.0%	Form 6-K FY2024Q2 Earnings Release ↗
Q1 2024	Mar 31, 2024	114	+16.3%	Form 6-K FY2024Q1 Earnings Release ↗
Q4 2023	Dec 31, 2023	112	+38.3%	Form 6-K FY2023Q4 Earnings Release ↗
Q3 2023	Sep 30, 2023	102	+29.1%	Form 6-K FY2023Q3 Earnings Release ↗
Q2 2023	Jun 30, 2023	100	+51.5%	Form 6-K FY2023Q2 Earnings Release ↗
Q1 2023	Mar 31, 2023	98	+55.6%	Form 6-K FY2023Q1 Earnings Release ↗
Q4 2022	Dec 31, 2022	81	+50.0%	Form 6-K FY2022Q4 Earnings Release ↗
Q3 2022	Sep 30, 2022	79	+61.2%	Form 6-K FY2022Q3 Earnings Release ↗
Q2 2022	Jun 30, 2022	66	+69.2%	Form 6-K FY2022Q2 Earnings Release ↗
Q1 2022	Mar 31, 2022	63	+90.9%	Form 6-K FY2022Q1 Earnings Release ↗
Q4 2021	Dec 31, 2021	54	+92.9%	Form 6-K FY2021Q4 Earnings Release ↗
Q3 2021	Sep 30, 2021	49	+133.3%	Form 6-K FY2021Q3 Earnings Release ↗
Q2 2021	Jun 30, 2021	39	+129.4%	Form 6-K FY2021Q2 Earnings Release ↗
Q1 2021	Mar 31, 2021	33	+200.0%	Form 6-K FY2021Q1 Earnings Release ↗
Q4 2020	Dec 31, 2020	28	+250.0%	Form 6-K FY2020Q4 Earnings Release ↗
Q3 2020	Sep 30, 2020	21	+425.0%	Form 6-K (filed 2021-07-30) ↗
Q2 2020	Jun 30, 2020	17	+750.0%	Form 6-K/A (filed 2020-07-31) ↗
Q1 2020	Mar 31, 2020	11	–	Form 6-K/A (filed 2020-07-31) ↗
Q4 2019	Dec 31, 2019	8	–	Form 6-K/A (filed 2020-07-31) ↗
Q3 2019	Sep 30, 2019	4	–	Form 6-K/A (filed 2020-07-31) ↗
Q2 2019	Jun 30, 2019	2	–	Form 6-K/A (filed 2020-07-31) ↗

Breakdown

What makes up lokelma (sodium zirconium cyclosilicate) — worldwide product sales ($m)

Cite this data

StockData. (2026). AstraZeneca Lokelma (sodium zirconium cyclosilicate) — Worldwide product sales ($M) ($M), quarterly Q2 2019–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med_lokelma_world

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.